Access to this content is restricted
Learning objectives:
- Understand the current status of minimal residual disease and plasma monitoring for resectable lung cancer
- Understand the role of plasma-based cfDNA testing in management of EGFR or ALK positive lung cancer
- Understand novel technologies in liquid biopsy for lung cancer
This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and to discuss how tumour heterogeneity and evolution assessed via liquid biopsy assays may improve lung cancer treatment strategies.s.